| Original language | English |
|---|---|
| Pages (from-to) | 365-380 |
| Number of pages | 16 |
| Journal | Journal of Infection and Chemotherapy |
| Volume | 19 |
| Issue number | 3 |
| DOIs | |
| Publication status | Published - 2013 Jun |
| Externally published | Yes |
Keywords
- Guideline
- MRSA
- Therapeutic drug monitoring
- Vancomycin
ASJC Scopus subject areas
- Microbiology (medical)
- Infectious Diseases
- Pharmacology (medical)
Access to Document
Other files and links
Cite this
- APA
- Standard
- Harvard
- Vancouver
- Author
- BIBTEX
- RIS
Practice guidelines for therapeutic drug monitoring of vancomycin : A consensus review of the Japanese Society of Chemotherapy and the Japanese Society of Therapeutic Drug Monitoring. / Matsumoto, Kazuaki; Takesue, Yoshio; Ohmagari, Norio; Mochizuki, Takahiro; Mikamo, Hiroshige; Seki, Masafumi; Takakura, Shunji; Tokimatsu, Issei; Takahashi, Yoshiko; Kasahara, Kei; Okada, Kenji; Igarashi, Masahiro; Kobayashi, Masahiro; Hamada, Yukihiro; Kimura, Masao; Nishi, Yoshifumi; Tanigawara, Yusuke; Kimura, Toshimi.
In: Journal of Infection and Chemotherapy, Vol. 19, No. 3, 06.2013, p. 365-380.Research output: Contribution to journal › Article › peer-review
}
TY - JOUR
T1 - Practice guidelines for therapeutic drug monitoring of vancomycin
T2 - A consensus review of the Japanese Society of Chemotherapy and the Japanese Society of Therapeutic Drug Monitoring
AU - Matsumoto, Kazuaki
AU - Takesue, Yoshio
AU - Ohmagari, Norio
AU - Mochizuki, Takahiro
AU - Mikamo, Hiroshige
AU - Seki, Masafumi
AU - Takakura, Shunji
AU - Tokimatsu, Issei
AU - Takahashi, Yoshiko
AU - Kasahara, Kei
AU - Okada, Kenji
AU - Igarashi, Masahiro
AU - Kobayashi, Masahiro
AU - Hamada, Yukihiro
AU - Kimura, Masao
AU - Nishi, Yoshifumi
AU - Tanigawara, Yusuke
AU - Kimura, Toshimi
N1 - Funding Information: Conflict of interest Yoshio Takesue has received a speaker’s honorarium from Pfizer Japan Inc., Astellas Pharma, Shionogi & Co., Ltd., MSD KK, Taisho Toyama Pharmaceutical Co., Ltd., and Dai-nippon Sumitomo Pharma. Yoshio Takesue has received Grant support from Pfizer Japan Inc., Astellas Pharma, Shionogi & Co., Ltd., MSD KK, Taisho Toyama Pharmaceutical Co., Ltd., Takeda Pharmaceutical Company Limited, and Dainippon Sumitomo Pharma. Norio Ohmagari has received speaker’s honorarium from Pfizer Japan Inc., Shionogi & Co., Ltd., Taisho Toyama Pharmaceutical Co., Ltd. Masafumi Seki has received a speaker’s honorarium from Pham. Corporations as follows: Astellas Inc., MSD Inc., Pfizer Japan Inc., Shionogi Inc., and Taisho Toyama Inc. Shunji Takakura has received speaker’s honorarium from Pfizer Japan Inc., Astellas Pharma Inc. Yusuke Tanigawara is a consultant to Meiji Seika Pharma Co., Ltd. Toshimi Kimura has received a speaker’s honorarium from Meiji Seika Pharma.
PY - 2013/6
Y1 - 2013/6
KW - Guideline
KW - MRSA
KW - Therapeutic drug monitoring
KW - Vancomycin
UR - http://www.scopus.com/inward/record.url?scp=84879245535&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84879245535&partnerID=8YFLogxK
U2 - 10.1007/s10156-013-0599-4
DO - 10.1007/s10156-013-0599-4
M3 - Article
C2 - 23673472
AN - SCOPUS:84879245535
VL - 19
SP - 365
EP - 380
JO - Journal of Infection and Chemotherapy
JF - Journal of Infection and Chemotherapy
SN - 1341-321X
IS - 3
ER -